Ignite Creation Date:
2024-05-05 @ 5:00 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00360256
Status:
COMPLETED
Last Update Posted:
2012-04-19
First Post:
2006-08-02
Brief Title:
Genetic Study of Liver Enzymes in Patients With Side Effects From Antidepressants
Sponsor:
Augusta University
Organization:
Augusta University
Study Overview
Official Title:
Pharmacogenetic Study of CYP450 2D6 and 2C19 in Patients With Significant Adverse Effects From Antidepressants
Status:
COMPLETED
Status Verified Date:
2012-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this pilot study is to determine the genetic polymorphism rate of CYP450 2D6 and 2C19 metabolic enzymes in patients with significant adverse effects from antidepressants compared to a population of patients who had no significant adverse effects from antidepressants metabolized by CYP2D6 and 2C19
The hypothesis for the proposed research is that the rate of 2D6 and 2C19 alleles that are associated with poor metabolizer status in the treatment-intolerant population will far exceed the rate found in patient population who takes antidepressants without adverse effects
The hypothesis for the proposed research is that the rate of 2D6 and 2C19 alleles that are associated with poor metabolizer status in the treatment-intolerant population will far exceed the rate found in patient population who takes antidepressants without adverse effects
Detailed Description:
Study Design This is a naturalistic study of sixty patients which will include 30 patients who had side significant adverse reactions from treatment with antidepressants metabolized by CYP2D6 and 2C19 TREATMENT-INTOLERANT group and 30 patients who responded to treatment with same group of antidepressants without significant adverse effects CONTROL group The study is expected to last for one year
Once recruitment subject consent and competency to participate have been achieved the diagnosis will be assessed through clinical interview aided by medical records when available A complete medication history will be taken including all known medications their doses and duration of use to determine exposure to antidepressants metabolized by CYP450 2D6 and 2C19 and absence of concomitant CYP 2D6 and 2C19 inhibitors A list of the antidepressants metabolized by CYP450 2D6 and 2C19 and their inhibitors is attached If exposure is confirmed each subject will be interviewed using the English version of UKU Udvalg for Kliniske Undersogelser Rating Scale14 to retrospectively assess their side effects from medications metabolized by CYP 2D6 and 2C19 enzymes We will use the modules 1 3 and 4 of the UKU for psychic autonomic and respectively other side effects Only patients who had marked side effects from one medication or either moderate or marked side effects from two medications metabolized by CYP 2D6 and 2C19 enzymes according with UKU will be included in the TREATMENT-INTOLERANT group Subjects who have none or mild adverse effects will be included in the CONTROL group The subject interview is expected to last approximately ninety minutes and will be conducted by a sub investigator Adriana Foster MD
The study participants will be asked to rinse mouth with water to remove food particles and spit saliva into a collection cup until the liquid level reaches the line indicated on the container 2ml We will use Oragene DNA self-collection kit DNA Genotek Inc Ottawa Ontario Canada
The saliva will be transported to GEM Labs located on MCG campus by research staff The genomic DNA will be extracted with the reagent and method supplied by the manufacturer Oragene This will be used as the template to amplify the relevant regions of CYP450 2D6 and 2C19 The PCR products will be randomly cleaved into 50 to 100 bp by digestion with DNase I These fragments will be further labeled with phycoerythrin PE a fluorescent dye The PE labeled fragments will be hybridized to the P450 Roche AmpliChip washed and scanned by the Affymetrix automated GeneChip fluidics Station 450Dx and the Affymetrix GeneChip scanner 3000Dx with GeneChip Operating Software Dx 113 The data will be analyzed by AmpliChip CYP450_US Data Analysis to determine the genotype for 2D6 it totally assesses 27 mutation sites deletion and duplication and 2C19 2 mutation sites Genotyping results will be analyzed by the same software to predict the phenotype ultra rapid extensive intermediate and poor metabolizer
Overall the study requires only one visit from the participant after interviewing and saliva sample have been completed the participants role in the research will be fulfilled This study will be carried out in its entirety at the Medical College of Georgia facilities We hope to demonstrate that the rate of 2D6 and 2C19 alleles that are associated with poor metabolizer status in the treatment-intolerant population will far exceed the rate found in patient population who takes antidepressants without adverse effects
Once recruitment subject consent and competency to participate have been achieved the diagnosis will be assessed through clinical interview aided by medical records when available A complete medication history will be taken including all known medications their doses and duration of use to determine exposure to antidepressants metabolized by CYP450 2D6 and 2C19 and absence of concomitant CYP 2D6 and 2C19 inhibitors A list of the antidepressants metabolized by CYP450 2D6 and 2C19 and their inhibitors is attached If exposure is confirmed each subject will be interviewed using the English version of UKU Udvalg for Kliniske Undersogelser Rating Scale14 to retrospectively assess their side effects from medications metabolized by CYP 2D6 and 2C19 enzymes We will use the modules 1 3 and 4 of the UKU for psychic autonomic and respectively other side effects Only patients who had marked side effects from one medication or either moderate or marked side effects from two medications metabolized by CYP 2D6 and 2C19 enzymes according with UKU will be included in the TREATMENT-INTOLERANT group Subjects who have none or mild adverse effects will be included in the CONTROL group The subject interview is expected to last approximately ninety minutes and will be conducted by a sub investigator Adriana Foster MD
The study participants will be asked to rinse mouth with water to remove food particles and spit saliva into a collection cup until the liquid level reaches the line indicated on the container 2ml We will use Oragene DNA self-collection kit DNA Genotek Inc Ottawa Ontario Canada
The saliva will be transported to GEM Labs located on MCG campus by research staff The genomic DNA will be extracted with the reagent and method supplied by the manufacturer Oragene This will be used as the template to amplify the relevant regions of CYP450 2D6 and 2C19 The PCR products will be randomly cleaved into 50 to 100 bp by digestion with DNase I These fragments will be further labeled with phycoerythrin PE a fluorescent dye The PE labeled fragments will be hybridized to the P450 Roche AmpliChip washed and scanned by the Affymetrix automated GeneChip fluidics Station 450Dx and the Affymetrix GeneChip scanner 3000Dx with GeneChip Operating Software Dx 113 The data will be analyzed by AmpliChip CYP450_US Data Analysis to determine the genotype for 2D6 it totally assesses 27 mutation sites deletion and duplication and 2C19 2 mutation sites Genotyping results will be analyzed by the same software to predict the phenotype ultra rapid extensive intermediate and poor metabolizer
Overall the study requires only one visit from the participant after interviewing and saliva sample have been completed the participants role in the research will be fulfilled This study will be carried out in its entirety at the Medical College of Georgia facilities We hope to demonstrate that the rate of 2D6 and 2C19 alleles that are associated with poor metabolizer status in the treatment-intolerant population will far exceed the rate found in patient population who takes antidepressants without adverse effects
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| HAC File 06-04-278 | None | None | None |